Today, Ambu announces its preliminary financial 2022/23 results. For the financial year 2022/23, EBIT before special items totalled DKK 302m, with an EBIT margin before special items of 6.3% (previous outlook: 5 – 6%), mainly driven by scale in OPEX and product mix.
PRELIMINARY FINANCIAL HIGHLIGHTS FOR THE FULL FINANCIAL YEAR 2022/23
Last year’s comparative figures are stated in brackets.
- Revenue was DKK 4,775m (DKK 4,444m), with organic growth of 7.6% (4%), driven by strong growth in Endoscopy Solutions. Reported growth for the year was 7.4% (11%).
- Gross margin was 56.8% (57.5%), mainly impacted by a strengthened product mix, driven by Endoscopy Solutions.
- EBIT before special items was DKK 302m (DKK 122m), corresponding to a margin of 6.3% (2.7%), mainly driven by scale in OPEX.
Based on the preliminary full-year 2023/23 results, Ambu’s organic revenue growth and EBIT margin before special items are as follows:
| Previous outlook | 9 October 2023 | |
| Organic revenue growth | 6 - 8% | 7.6% |
| EBIT margin before special items | 5 - 6% | 6.3% |
The stated preliminary results for the full financial year 2022/23 are unaudited.
Ambu will release its Annual Report on 8 November 2023.
Ambu A/S
Baltorpbakken 13 2750 Ballerup
Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.Ambu.com
CONTACT
Investors
Anders Hjort
Head of Investor Relations
anhj@ambu.com
+45 2892 8881
Media
Tine Bjørn Schmidt
Head of Corporate Communications
tisc@ambu.com
+45 2264 0697
ABOUT AMBU
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit Ambu.com.
Attachment
